On the other hand, our data were consistent with those of a previous study which revealed that the SIGMAR1 inhibitor decreased cell surface PD-L1 expression and suppressed the functional interaction of PD-1 and PD-L1 in a coculture of T cells and breast and prostate cancer cells [7]. Here, SIGMAR1 is linked to prostate cancer.